We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
Read MoreHide Full Article
Key Takeaways
Novo Nordisk gained FDA approval to expand Rybelsus' label for cardiovascular risk reduction.
The SOUL study showed a 14% relative risk drop in major CV events for Rybelsus versus placebo.
This milestone strengthens semaglutide's position across diabetes, obesity, and heart disease care.
Novo Nordisk (NVO - Free Report) received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults with type II diabetes (T2D).
This approval makes Rybelsus the first and only oral GLP-1 therapy approved to lower the risk of major adverse cardiovascular events (MACE), including CV death, heart attack, or stroke, in high-risk T2D patients, regardless of prior CV history. The indication supports both primary prevention, by managing risk factors in high-risk individuals, and secondary prevention, by reducing the likelihood of recurrent events in those with a previous serious CV event.
Please note that the FDA first approved Rybelsus in 2019 as the only oral GLP-1 therapy to be used alongside diet and exercise for improving blood sugar control in adults with T2D. Last month, Rybelsus’ label was also expanded in the EU to reflect MACE risk reduction in adult T2D patients.
Year to date, shares of Novo Nordisk have plunged 35.2% against the industry’s 5.1% growth.
Image Source: Zacks Investment Research
FDA Clears NVO’s Rybelsus for MACE After Phase III Success
The FDA’s decision is supported by positive data from the phase IIIb SOUL study, which demonstrated that Rybelsus significantly reduced the risk of CV events in this high-risk population, marking an important milestone for the company’s oral GLP-1 platform.
Results from the SOULstudy showed that Rybelsus, in addition to standard of care, achieved a statistically significant 14% relative risk reduction in MACE compared to placebo. Over the study’s four-year follow-up, 12% of patients in the Rybelsus group experienced a CV event compared to 13.8% in the placebo group, representing a 2% absolute risk reduction at three years. Per Novo Nordisk, the SOUL study findings strengthen the growing body of clinical and real-world evidence demonstrating semaglutide’s CV benefits beyond glycemic control, a key concern for people with T2D.
The safety profile of Rybelsus in the SOUL study was generally consistent with previous studies. Serious adverse events were slightly lower in the Rybelsus group compared to placebo, with cardiac disorders and infections/infestations being the most common. However, gastrointestinal side effects and discontinuation rates due to adverse events were higher in the Rybelsus group compared to placebo.
Novo Nordisk also markets its semaglutide medicines as Ozempic and Wegovy injections for diabetes and obesity indications, respectively.
The company has filed a supplemental regulatory application in the United States seeking approval of a 25 mg oral formulation of semaglutide (Wegovy pill) for obesity and CV disease, which could become the first oral GLP-1 therapy for chronic weight management, if approved. A decision is expected later this year. Label expansion is also being sought for Ozempic in treating peripheral artery disease in the United States and the European Union.
By broadening indications and introducing new formulations, Novo Nordisk is reinforcing semaglutide’s role as a cornerstone therapy across diabetes, obesity and cardiometabolic diseases, supporting long-term revenue expansion.
In the past 60 days, estimates for Chemomab Therapeutics’ 2025 loss per share have narrowed from $2.40 to 60 cents. Loss per share estimates for 2026 have narrowed from $2.80 to $1.00 during the same period. CMMB stock has plunged 55.1% year to date.
Chemomab Therapeutics’ earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with an average surprise of 26.25%.
In the past 60 days, estimates for Alnylam’s 2025 earnings per share have risen from $3.34 to $3.81. During the same period, earnings per share for 2026 have increased from $9.23 to $9.97. Year to date, ALNY’s shares have surged 99.9%.
Alnylam’s earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with an average surprise of 348.36%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share have risen from $7.25 to $7.29. During the same period, earnings per share for 2026 have increased from $7.74 to $7.81. Year to date, ANIP’s shares have rallied 66.5%.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with an average surprise of 22.66%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
Key Takeaways
Novo Nordisk (NVO - Free Report) received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults with type II diabetes (T2D).
This approval makes Rybelsus the first and only oral GLP-1 therapy approved to lower the risk of major adverse cardiovascular events (MACE), including CV death, heart attack, or stroke, in high-risk T2D patients, regardless of prior CV history. The indication supports both primary prevention, by managing risk factors in high-risk individuals, and secondary prevention, by reducing the likelihood of recurrent events in those with a previous serious CV event.
Please note that the FDA first approved Rybelsus in 2019 as the only oral GLP-1 therapy to be used alongside diet and exercise for improving blood sugar control in adults with T2D. Last month, Rybelsus’ label was also expanded in the EU to reflect MACE risk reduction in adult T2D patients.
Year to date, shares of Novo Nordisk have plunged 35.2% against the industry’s 5.1% growth.
Image Source: Zacks Investment Research
FDA Clears NVO’s Rybelsus for MACE After Phase III Success
The FDA’s decision is supported by positive data from the phase IIIb SOUL study, which demonstrated that Rybelsus significantly reduced the risk of CV events in this high-risk population, marking an important milestone for the company’s oral GLP-1 platform.
Results from the SOULstudy showed that Rybelsus, in addition to standard of care, achieved a statistically significant 14% relative risk reduction in MACE compared to placebo. Over the study’s four-year follow-up, 12% of patients in the Rybelsus group experienced a CV event compared to 13.8% in the placebo group, representing a 2% absolute risk reduction at three years. Per Novo Nordisk, the SOUL study findings strengthen the growing body of clinical and real-world evidence demonstrating semaglutide’s CV benefits beyond glycemic control, a key concern for people with T2D.
The safety profile of Rybelsus in the SOUL study was generally consistent with previous studies. Serious adverse events were slightly lower in the Rybelsus group compared to placebo, with cardiac disorders and infections/infestations being the most common. However, gastrointestinal side effects and discontinuation rates due to adverse events were higher in the Rybelsus group compared to placebo.
Novo Nordisk also markets its semaglutide medicines as Ozempic and Wegovy injections for diabetes and obesity indications, respectively.
The company has filed a supplemental regulatory application in the United States seeking approval of a 25 mg oral formulation of semaglutide (Wegovy pill) for obesity and CV disease, which could become the first oral GLP-1 therapy for chronic weight management, if approved. A decision is expected later this year. Label expansion is also being sought for Ozempic in treating peripheral artery disease in the United States and the European Union.
By broadening indications and introducing new formulations, Novo Nordisk is reinforcing semaglutide’s role as a cornerstone therapy across diabetes, obesity and cardiometabolic diseases, supporting long-term revenue expansion.
Novo Nordisk A/S Price and Consensus
Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote
NVO’s Zacks Rank and Stocks to Consider
Novo Nordisk currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the overall medical sector are Chemomab Therapeutics (CMMB - Free Report) , Alnylam Pharmaceuticals (ALNY - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) . While CMMB currently sports a Zacks Rank #1 (Strong Buy), ALNY and ANIP carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Chemomab Therapeutics’ 2025 loss per share have narrowed from $2.40 to 60 cents. Loss per share estimates for 2026 have narrowed from $2.80 to $1.00 during the same period. CMMB stock has plunged 55.1% year to date.
Chemomab Therapeutics’ earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with an average surprise of 26.25%.
In the past 60 days, estimates for Alnylam’s 2025 earnings per share have risen from $3.34 to $3.81. During the same period, earnings per share for 2026 have increased from $9.23 to $9.97. Year to date, ALNY’s shares have surged 99.9%.
Alnylam’s earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with an average surprise of 348.36%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share have risen from $7.25 to $7.29. During the same period, earnings per share for 2026 have increased from $7.74 to $7.81. Year to date, ANIP’s shares have rallied 66.5%.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with an average surprise of 22.66%.